Mymetics Corp. (MYMX.OB) Acquires Malaria Vaccine, Pursuing European Union Regulations
Vaccine development company Mymetics Corp. (OTCBB: MYMX) today announced the acquisition of a malaria vaccine from Previon Biotech AG, a privately owned Swiss biopharmaceutical company. The preventative vaccine was successfully completed in human clinical trial phases I and II in Switzerland and the UK; more studies are to follow. “We are pleased with this acquisition which allows us to start feeding a pipeline of products for the future, in addition to our preventive HIV/AIDS vaccine,” Christian J. F. Rochet, CEO and president of Mymetics Corp. stated in the press release. “There is a pressing need within the global community for…